CA2800182A1 - Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof - Google Patents

Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof Download PDF

Info

Publication number
CA2800182A1
CA2800182A1 CA2800182A CA2800182A CA2800182A1 CA 2800182 A1 CA2800182 A1 CA 2800182A1 CA 2800182 A CA2800182 A CA 2800182A CA 2800182 A CA2800182 A CA 2800182A CA 2800182 A1 CA2800182 A1 CA 2800182A1
Authority
CA
Canada
Prior art keywords
influenza virus
antibody
influenza
virus
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2800182A
Other languages
English (en)
French (fr)
Inventor
Adolfo Garcia-Sastre
Peter Palese
Taia T. Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of CA2800182A1 publication Critical patent/CA2800182A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
CA2800182A 2009-05-26 2010-05-26 Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof Abandoned CA2800182A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18126309P 2009-05-26 2009-05-26
US61/181,263 2009-05-26
US22430209P 2009-07-09 2009-07-09
US61/224,302 2009-07-09
US30589810P 2010-02-18 2010-02-18
US61/305,898 2010-02-18
PCT/US2010/036170 WO2010138564A1 (en) 2009-05-26 2010-05-26 Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof

Publications (1)

Publication Number Publication Date
CA2800182A1 true CA2800182A1 (en) 2010-12-02

Family

ID=42352512

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2800182A Abandoned CA2800182A1 (en) 2009-05-26 2010-05-26 Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof

Country Status (6)

Country Link
US (3) US8673314B2 (enExample)
EP (1) EP2435475B1 (enExample)
JP (3) JP5941841B2 (enExample)
AU (1) AU2010254136B2 (enExample)
CA (1) CA2800182A1 (enExample)
WO (1) WO2010138564A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063127A1 (en) 2009-11-18 2011-05-26 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
EP2413962A1 (en) * 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
AU2011217903B2 (en) * 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
ES2728433T3 (es) * 2011-04-21 2019-10-24 Ology Bioservices Inc Procedimientos para aislar y cuantificar un antígeno de vacunas
AR087364A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
JP6253580B2 (ja) * 2011-08-10 2017-12-27 ランケナー インスティテュート フォー メディカル リサーチ 自己免疫および炎症性疾患の治療のための方法および組成物
GB201115214D0 (en) * 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
IN2014CN02114A (enExample) 2011-09-20 2015-05-29 Sinai School Medicine
SG11201402780UA (en) 2011-12-02 2014-10-30 Aimm Therapeutics Bv Influenza a virus specific antibodies
EA028433B1 (ru) * 2012-03-08 2017-11-30 Янссен Вэксинс Энд Превеншн Б.В. Антитело, связывающееся с вирусами гриппа b и его применение
CN102621320B (zh) * 2012-03-20 2014-07-02 中国检验检疫科学研究院 一种用于快速检测人禽流感病毒的非诊断性双抗体夹心法
US9549993B2 (en) 2012-10-02 2017-01-24 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated with antibodies to activate matripase
EP4154907A1 (en) 2012-12-18 2023-03-29 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
EP3003373A4 (en) 2013-03-14 2016-10-19 Contrafect Corp COMPOSITION AND METHODS BASED ON INTRANASALLY RELEASED NEUTRALIZING ANTIBODIES FOR IMPROVED THERAPEUTIC EFFECTIVENESS
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2014143886A2 (en) * 2013-03-15 2014-09-18 Edimer Pharmaceuticals, Inc. Anti-ectodysplasin antibodies
US20160200799A1 (en) * 2013-08-23 2016-07-14 Fujita Health University Anti-influenza virus neutralizing antibody
SG10202103140XA (en) * 2013-10-02 2021-05-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
RU2720282C1 (ru) 2014-02-04 2020-04-28 Контрафект Корпорейшн Антитела, подходящие для пассивной иммунизации против гриппа, и их композиции, комбинации и способы применения
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
JP2018518151A (ja) * 2015-03-27 2018-07-12 ユニバーシティ オブ サザン カリフォルニア Ｂ７−ｈ４発現充実性腫瘍を処置するためのｃａｒ ｔ細胞
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
EP3429586A4 (en) 2016-03-18 2020-03-11 Rutgers, the State University of New Jersey TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO-CLAVABLE LINKAGES
EP3455251A4 (en) 2016-05-09 2020-04-22 Icahn School of Medicine at Mount Sinai WIDE NEUTRALIZING HUMAN ANTI-CYTOMEGALOVIRUS ANTIBODIES AND METHODS OF USE
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US10766968B2 (en) 2017-08-23 2020-09-08 Brown University Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
WO2019040685A1 (en) * 2017-08-23 2019-02-28 Brown University METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
AU2023283550A1 (en) * 2022-06-09 2024-11-21 Santa Ana Bio, Inc. Antibodies targeting c-kit and/or siglec and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US5182192A (en) * 1987-03-27 1993-01-26 The Wistar Institute Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6337070B1 (en) * 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
WO1994016109A1 (en) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
NZ517903A (en) 1999-09-24 2003-10-31 Smithkline Beecham Biolog S One dose intranasal influenza virus vaccine with split influenza viral antigens
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6632620B1 (en) * 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
CA2514177A1 (en) * 2003-01-29 2004-08-12 Josef Michl Tolerance-induced targeted antibody production
ATE426412T1 (de) 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP2530147B1 (en) 2004-05-25 2014-09-10 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
CN101163714A (zh) 2005-02-24 2008-04-16 马萨诸塞大学 流感病毒核酸、多肽及其用途
AU2006252406B2 (en) 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
JP4758148B2 (ja) * 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
WO2007052058A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
WO2007066334A1 (en) 2005-12-06 2007-06-14 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
CA2657849A1 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
SG173337A1 (en) 2006-07-21 2011-08-29 California Inst Of Techn Targeted gene delivery for dendritic cell vaccination
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2174957B1 (en) 2007-06-15 2016-03-16 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
JP5187883B2 (ja) * 2007-07-18 2013-04-24 独立行政法人科学技術振興機構 抗原ペプチドおよびその利用
WO2009025770A2 (en) * 2007-08-17 2009-02-26 Wyeth A heterologous prime-boost immunization regimen
FR2921387B1 (fr) 2007-09-26 2012-04-20 Sanofi Pasteur Procede de production du virus de la grippe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
RU2010127156A (ru) 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
EP2698380A1 (en) 2008-03-28 2014-02-19 Sea Lane Biotechnologies, LLC Neutralizing molecules to viral antigens
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
WO2010130636A1 (en) 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
CA2762042C (en) 2009-06-24 2012-11-20 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
JP5845180B2 (ja) 2009-07-30 2016-01-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルス及びそれらの使用
AU2011217903B2 (en) 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
EP2596017B1 (en) 2010-07-22 2019-04-03 John W. Schrader Cross-protective antibody against influenza viral infection
IN2014CN02114A (enExample) 2011-09-20 2015-05-29 Sinai School Medicine
EP4154907A1 (en) 2012-12-18 2023-03-29 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
US20110027270A1 (en) 2011-02-03
US20140170163A1 (en) 2014-06-19
EP2435475A1 (en) 2012-04-04
JP5941841B2 (ja) 2016-06-29
AU2010254136A1 (en) 2012-01-19
JP2018064580A (ja) 2018-04-26
US9175069B2 (en) 2015-11-03
US8673314B2 (en) 2014-03-18
WO2010138564A1 (en) 2010-12-02
EP2435475B1 (en) 2018-10-17
AU2010254136B2 (en) 2016-09-29
JP2012527899A (ja) 2012-11-12
JP2016127846A (ja) 2016-07-14
US20150239960A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
US9175069B2 (en) Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
US12030928B2 (en) Anti-influenza B virus neuraminidase antibodies and uses thereof
US12233123B2 (en) Influenza virus hemagglutinin proteins and uses thereof
US9701723B2 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
US10544207B2 (en) Antibodies against influenza virus hemagglutinin and uses thereof
CN101883789B (zh) 特异于流感病毒h5亚型或者n1亚型的血凝素和神经氨酸酶的单克隆抗体及其应用
JP2016199557A (ja) インフルエンザウイルスワクチン及びその使用
CN101072795A (zh) 针对流感病毒m2蛋白的人单克隆抗体及其制备和使用方法
US20220153873A1 (en) Anti-influenza b virus neuraminidase antibodies and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150320

FZDE Discontinued

Effective date: 20181002

FZDE Discontinued

Effective date: 20181002